MPCCC’s Precision Oncology Program is establishing a coordinated platform across MPCCC partner health services to give patients access to the latest technologies involving genomic tumour profiling. Research breakthroughs, particularly in genomics, are opening up exciting new pathways for personalised cancer treatment, and this program will ensure targeted therapies, immunotherapies or referral to appropriate clinical trials are available to our patients.
Key to the MPCCC Precision Oncology Program’s engagement strategy are Molecular Tumour Board meetings and the Precision Oncology Seminar Series, which utilise video-conferencing technology to encourage cross-site participation. Since the program began in September 2018, 3 Molecular Tumour Boards focused on 3 different tumour streams have been established: Myeloproliferative Neoplasms, led by Professor Andrew Perkins; Lymphoma, which had a brief hiatus from October-December 2019 and will re-commence in 2020; and Acute Myeloid Leukaemia and Minimal Residual Disease, led by Associate Professor Andrew Wei. Precision Oncology Seminars are held at different locations across MPCCC partners and feature including presentations from both local and interstate and international guest speakers.
The MPCCC Precision Oncology Program will provide a multidisciplinary platform for clinicians to apply precision medicine in a manner that supports excellence in patient care, and provides new hope for vastly improved outcomes for patients utilising ground-breaking precision oncology techniques.
See here for details of the project team. For more information, contact Vikki Marshall on email@example.com or 0448 986 722.
MPCCC acknowledges the support of the Victorian State Government.